Parkinson Disease
Conditions
Keywords
Parkinson's disease, Neurodegenerative Diseases, Central Nervous System Diseases, Parkinsonian Disorders, Movement Disorders, GBA1 gene, BIA 28-6156, ACTIVATE, Compassionate Use
Brief summary
This Program is designed to provide continued access BIA 28-6156, free and compassionately for an eligible patient previously enrolled in the BIA 28-6156-201 (ACTIVATE) clinical study and that had completed the study.
Detailed description
A patient taking part in this program will be provided with a 60mg dosage of BIA 28-6156. This will be taken orally once daily (OD) for the duration of the program, currently scheduled to run for 27 months. Patients will visit the site approximately every 3 months for a drug re-supply. At these visits, the treating physician will reassess if the patient should continue with the treatment. In case of tolerability concerns, the dose of BIA 28-6156 will be stopped per the treating physician's assessment. The treating physician should discontinue treatment for the patient and/or withdraw the patient from this program if he/she believes that continuation would be detrimental to the patient's well-being. Patients may voluntarily withdraw from treatment at any time, for any reason.
Interventions
DRUGBIA 28-6156
60mg dosage of BIA 28-6156 taken orally once daily
Sponsors
Bial R&D Investments, S.A.
Eligibility
Sex/Gender
ALL
Inclusion criteria
1. A patient who completes Part B (Double Blind Treatment arm) of the ACTIVATE study supplied by BIAL R\&D Investments, S.A., and falls within one week of completing the safety follow up visit from the ACTIVATE study. 2. A patient is willing to provide written informed consent prior to initiating treatment, in accordance with International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. A patient who, in the opinion of the treating physician will likely adhere to the program. 3. A patient's treating physician believes the patient could benefit from treatment with BIA 28-6156. 4. Patient has received approval from Supplier or its designee following the treating physician request submission. 5. If a sexually active man or a woman of childbearing potential, the patient agrees to use highly effective birth control or to remain abstinent during the program and for 30 days after the last dose of BIA 28-6156. Acceptable (highly effective) methods of contraception for this study include hormonal contraceptives (combined oral contraceptive, patch, vaginal ring, injectable, or implant); intrauterine device or system; complete abstinence from sexual intercourse if this is the patient's usual and preferred lifestyle; or sexual partner with surgical sterilization (e.g., tubal ligation, hysterectomy and/or bilateral oophorectomy.
Exclusion criteria
1. A patient that has previously discontinued for any reason from the BIA 28-6156-201 clinical study. 2. A patient who is pregnant, may be pregnant, lactating, or planning to be pregnant.
Countries
Italy, Portugal, Spain, United Kingdom, United States
Outcome results
None listed